Daniel A. Anaya, Yan Xing, Lei Feng, Xuelin Huang, Luis H. Camacho, Merrick I. Ross, Jeffrey E. Gershenwald, Jeffrey E. Lee, Paul F. Mansfield and Janice N. Cormier Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease Cancer 112
Version of Record online: 4 MAR 2008 | DOI: 10.1002/cncr.23399
In this retrospective review, the authors found that the use of adjuvant high-dose interferon for patients with stage III melanoma was associated with improved recurrence-free survival, with the most striking benefit noted for patients with stage IIIA disease.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field